Pawlak Joanna, Zietkowski Ziemowit, Bodzenta-Łukaszyk Anna
Klinika Alergologii i Chorób Wewnetrznych USK w Białymstoku.
Postepy Hig Med Dosw (Online). 2009 Dec 16;63:634-42.
Asthma is a disease with a complex pathogenesis and differentiated clinical picture with airway inflammation in its background. Many cells and cell-released substances are engaged in the course of the disease. The basic treatment strategy in asthma is based on chronic administration of inhaled glucocorticosteroids (with a strong anti-inflammatory effect) and beta2-adrenoreceptor agonists (bronchodilatory effect). Much attention has been recently paid to the effects of other medicines on mechanisms important in the pathogenesis of asthma, including beta-blockers and statins. Many researchers have suggested a potentially useful role of some beta-blockers in chronic asthma therapy, particularly considering their effect on the pharmacodynamics of beta receptors in the bronchi. Moreover, statins, due to their anti-inflammatory and immunomodulatory effects, can also be useful in the management of asthma.
哮喘是一种发病机制复杂、临床表现多样且以气道炎症为背景的疾病。许多细胞和细胞释放的物质参与了该疾病的进程。哮喘的基本治疗策略基于长期吸入糖皮质激素（具有强大的抗炎作用）和β2肾上腺素能受体激动剂（支气管扩张作用）。最近，人们对其他药物对哮喘发病机制中重要机制的影响给予了很多关注，包括β受体阻滞剂和他汀类药物。许多研究人员提出，一些β受体阻滞剂在慢性哮喘治疗中可能具有有益作用，特别是考虑到它们对支气管中β受体药效学的影响。此外，他汀类药物由于其抗炎和免疫调节作用，在哮喘管理中也可能有用。
